

Chapter 12

Drug-Dietary Interactions: Over-the-Counter Medications, Herbs, and Dietary Supplements



Laurence J. Kinsella, George T. Grossberg, and Neha Prakash

Case Vignette

A 35-year-old man presents with sudden onset of severe throbbing headache, nausea, and light sensitivity. He has no prior history of headaches and migraine. In the emergency department, his examination is normal except for mild neck stiffness and photophobia. Computed tomography (CT) of the brain was unrevealing, and lumbar puncture showed no evidence of subarachnoid hemorrhage. Magnetic resonance imaging (MRI) was performed demonstrating multiple small white matter lesions on FLAIR sequences with normal diffusion-weighted imaging. An MR angiogram demonstrated multiple segmental arterial narrowing in the branches of the middle cerebral arteries. When questioned further, he admitted to using Hydroxycut for weight loss in the last 15 days. Symptoms resolved when the supplement was stopped [1].

L. J. Kinsella, MD (✉)

Department of Neurology, SSM Neuroscience Institute, St. Louis, MO, USA

Department of Neurology, St. Louis University School of Medicine, St. Louis, MO, USA

e-mail: Laurence.Kinsella@ssmhealth.com

G. T. Grossberg, MD

Division of Geriatric Psychiatry, Department of Psychiatry & Behavioral Neuroscience,
St. Louis University School of Medicine, St. Louis, MO, USA

N. Prakash, MD

Department of Neurology, Northwestern University Feinberg School of Medicine,
Chicago, IL, USA

Introduction

Herbal medications have been used throughout human history. Since the DHEAS Act of 1994, there has been an explosion of new products marketed to a welcoming public. Dietary supplements are far less rigorously regulated than drugs by the Federal Drug Administration (FDA). The FDA defines dietary supplement as “a product intended for ingestion that contains a ‘dietary ingredient’ intended to further nutritional value to supplement the diet. A ‘dietary ingredient’ may be one, or any combination, of the following substances: a vitamin, a mineral, an herb or other botanical” [2]. There are over 50,000 dietary supplements registered with the Office of Dietary Supplements, a division of the National Institutes of Health. The most popular include vitamin and minerals (43%), specialty supplements for weight loss and sexual health (20%), botanicals (20%), and sports (16%) [3]. Over half of American adults take dietary supplements, and about a third of older adults take over the counter medications (OTCs) [4].

Dietary supplements of interest to neurologists include the migraine remedies feverfew, riboflavin, magnesium and butterbur extract. Galantamine, a plant extract, is used in the treatment of Alzheimer’s disease [3].

Without claiming to treat a disease, the dietary supplement industry may promote health and wellness benefits without the requirement of randomized controlled trials, although a number do exist [3].

Herbs may be complicated mixtures of organic and inorganic compounds, some with potentially toxic ingredients [5]. The strength and quantity of the active ingredient may differ among manufacturers. There are efforts to standardize supplement ingredients for consistency and safety [6]. As the use of herbs and over-the-counter (OTC) medications increases, so too the risk of interactions with prescribed medications. This review highlights potential side effects and drug interactions possible with OTCs, herbal medicines, and dietary supplements without undermining the potential, though often unproven, benefits when used appropriately.

In one study, 43% of patients in an outpatient practice were taking both a dietary supplement with prescribed medication. The most common products included vitamins and minerals, garlic, *Ginkgo biloba*, saw palmetto, and ginseng.

About 6% had potentially serious drug-OTC interactions [7]. This included patients taking both calcium and ciprofloxacin (reduced absorption of fluoroquinolones), potassium plus lisinopril (risk for hyperkalemia), and St John’s wort plus paroxetine (increased risk of serotonin syndrome) [8].

Clinical Syndromes of Drug-Diet-OTC Toxicity

The presentation of herbal and OTC medication toxicity has a wide spectrum (Table 12.1). The use of excessive diphenhydramine as a sleep aid may induce somnolence and confusion, especially when combined with a beta blocker or other

Table 12.1 Some neurologic syndromes associated with dietary supplements

Neurologic syndrome	Medication examples
Reversible cerebral vasoconstriction syndrome	Sympathomimetic amines (khat, ephedra, ma huang, pseudoephedrine), caffeine, marijuana [9]
Drug-induced seizure	Khat, HCA, caffeine, diphenhydramine [10] Gingko [11]
Serotonin syndrome	Tryptophan [12]
Large fiber neuropathy	Pyridoxine (B6) [13, 14]
Rhabdomyolysis	Hydroxycut [15]
Acute renal failure	Orlistat [16]
Syncope from prolonged QT	Energy drinks, guarana, caffeine [17] diphenhydramine [18]
Intracerebral hemorrhage	Ginseng, garlic, gingko [19–21]
Delirium	Dextromethorphan, diphenhydramine [22]

Table 12.2 Dietary supplement toxicity

Agent	Mechanism of injury	Toxicity symptoms
Pyridoxine (vitamin B6)	Enzyme inhibition [27]	Large fiber neuropathy, sensory ataxia [13, 14, 28]
Chinese herbal remedies	Heavy metal intoxication [29]	Neuropathy, encephalopathy [5, 29]
Metabolife	Excitotoxicity (yohimbine, guarana)	QTc prolongation, arrhythmia [30]
Caffeine	Excitotoxicity	Cardiac arrhythmia [30]

inhibitor of P450 2D6. Vasoactive compounds such as pseudoephedrine (also known as ephedra and ma huang) in cough and weight loss remedies may induce stroke, seizures, or thunderclap headache. Since 2004, the FDA has banned the use of ephedra-containing compounds in dietary supplements [23].

One striking presentation of toxicity is reversible cerebral vasoconstriction syndrome (RCVS). It often presents as a thunderclap headache with or without neurological deficits. Angiography may show multifocal cerebral artery vasospasm [1, 9, 24]. RCVS has been reported secondary to vasoactive substances such as pseudoephedrine, caffeine, energy drinks, marijuana, and other naturally occurring stimulants. Another example is *khat*, a plant (*Catha edulis*) chewed in countries like Yemen. Its active ingredient is an amphetamine-like agent that may trigger cerebral vasospasm, stroke, and seizure [25, 26].

Dietary Supplement Toxicity

Toxicity may be direct or secondary to an interaction with a prescribed or OTC medication. Some examples of toxicity from dietary supplements are seen Table 12.2. Pyridoxine in doses >200 mg per day for several months or >1000 mg per day for several days may induce a severe peripheral neuropathy [13, 14, 31]. Chinese herbal remedies may be laced with heavy metals [5].

Mechanism of the Drug-Diet Interaction

Over-the-Counter Medications

Increasing over-the-counter (OTC) medication use has been associated with increasing reports of toxicity and abuse (Tables 12.3 and 12.4) [40]. OTCs can be categorized as:

1. Medications for common ailments (cough syrup, analgesics, antiseptics, antifungal/antibacterials, motion sickness medications, etc.)
2. Herbal and dietary supplements
3. Weight loss supplements

Finkelstein found that one-fourth of all poisoning cases in the pediatric population seen in an ER involve improper use of OTCs [22]. Abuse and misuse of OTCs has been associated with depression [41].

Dextromethorphan is a commonly consumed cough remedy. Side effects are dose dependent and vary from mild sedation at low doses to hallucinations and

Table 12.3 Ten examples of potential drug-OTC interactions

OTC	Rx drug	Interaction
Diphenhydramine	Metoprolol	Bradycardia
	SSRI/SNRI	Serotonin syndrome
Pseudoephedrine	SSRI/SNRI	Serotonin syndrome
Acetaminophen	Alcohol	Increased toxic acetaminophen metabolites, increased alcohol levels [32]
Caffeine	Alcohol	Inhibitor of CYP1A2, raising caffeine levels [30]
Aspirin	Valproate	Displaces VPA, raising levels [33]
Omeprazole	Ciprofloxacin	Reduced Cipro levels, CYP1A2 vs malabsorption [34]
Fexofenadine	Ketoconazole	Increased fexofenadine levels [35]
Dextromethorphan	Quinidine	Increased serum concentrations due to 2D6 inhibition, now FDA approved for pseudobulbar affect (NUEDEXTA) [36]
Loperamide	Quinidine	CNS depression due to PGP inhibition within blood-brain barrier [37]

Table 12.4 Mechanisms of drug-diet interactions

Example	Adverse event	Mechanism
Diphenhydramine and alcohol	Additive sedative properties	Pharmacodynamic interaction
Fluvoxamine and caffeine	Increased caffeine levels [38]	P450 1A2 enzyme inhibition [30]
Amitriptyline and St John's wort	Low amitriptyline levels [39]	P450 3A4 enzyme induction
Statins and grapefruit juice	Myalgias, statin myopathy	Inhibits first-pass metabolism of 3A4 enzyme
Warfarin and spinach	Reduced INR, increase thrombotic risk	Incomplete vitamin K inhibition

ataxia and coma at higher doses. In a review of adolescent overdose, 25% are OTC medications, and half were due to dextromethorphan [22]. Other common agents of overdose include diphenhydramine [42], aspirin, acetaminophen, motion sickness agents such as dramamine, and pseudoephedrine.

Weight Loss Supplements

Weight loss supplements are popular and are a dominant player in the dietary supplement industry. A quick review of Amazon shows hundreds of products marketed to the public [43]. Some of the most widely used supplements and their ingredients are listed in Table 12.5. Hydroxycut is among the most popular weight loss supplements. Prior to 2004, it contained both ephedra and caffeine. It has had several reformulations due to reports of toxicity and was pulled off the market in 2009 following an FDA warning [55]. Current versions contain up to 400 mg of caffeine. Hydroxycut has been linked with liver toxicity [44, 45], seizures [46], RCVS [1], mania [47], and rhabdomyolysis [48].

Hydroxycitric acid (HCA) is the active ingredient of *Garcinia cambogia extract* (MOA), a fruit rind of *Garcinia gummi-gutta*, and is most commonly used in weight loss supplements. It is purported to regulate serotonin levels, promote lipid oxidation, and inhibit lipid synthesis [56]. Although HCA has potential beneficial effects, drug interactions and adverse effects do occur. Serotonin syndrome has been

Table 12.5 Weight loss supplements and toxicity

Weight loss supplement brand	Ingredients	Active ingredient known	Toxicity reported
Pure <i>Garcinia cambogia</i> extract 95% HCA	<i>Garcinia cambogia</i> extract (HCA), potassium, calcium, chromium	Hydroxycitric acid (HCA)	Liver toxicity [44, 45], seizures [46], RCVS [1], mania [47], and rhabdomyolysis [48]
Hydroxycut	230–340 mg caffeine, green coffee extract, yohimbe, L-theanine, <i>Coleus forskohlii</i>	Green coffee bean extract	Manic episodes [49] Serotonin syndrome with escitalopram [50] QTc prolongation with yohimbine [30]
Alli orlistat FDA approved	Orlistat (60 Mg). Inactive ingredients: FD&C Blue No. 2, edible ink, gelatin, iron oxide, microcrystalline cellulose, povidone, sodium lauryl sulfate, sodium starch glycolate, talc, titanium dioxide	Orlistat	Hepatotoxic [51] and nephrotoxic [16] Deficiency of fat-soluble vitamins [52] Inhibits absorption of some medications [53]
NatureWise CLA 1250	Safflower oil: 80% conjugated linoleic acid (CLA)	Conjugated linoleic acid (CLA)	Hepatic steatosis in animal studies [54]

reported in a woman on escitalopram and *Garcinia* for weight loss [50]. *Garcinia* has also been associated with manic episodes [49].

Another weight loss supplement, *orlistat*, is an over-the-counter, semisynthetic lipase inhibitor. It blocks gastric and pancreatic lipase, leading to a 30% reduction in absorption of dietary triglycerides [57]. Orlistat may reduce levels of cyclosporine [53], leading to loss of immunosuppression. It may cause hepatotoxic [51] and nephrotoxic [16] effects. Because of its mechanism of action, it has the potential to cause deficiency of fat-soluble vitamins [52]. Conjugated linoleic acid has been associated with hepatic steatosis in animal studies [54].

Other Herbal and Dietary Supplements

What follows is a list of dietary supplements that have been associated with direct toxicity or drug-diet interactions. The supporting literature is often weak and based upon case reports (Tables 12.6 and 12.7). More rigorous clinical studies of some previously suspect dietary supplements such as garlic, ginkgo, ginger, and cranberry show no significant interactions at recommended doses; however, megadosing may be associated with greater toxicity. The most important dietary supplement to cause clinically relevant interactions with prescription drugs is St John's wort [58, 59].

St John's wort has been used successfully for mild to moderate depression [66]. When taken together with an SSRI or SNRI, it may increase the risk of serotonin syndrome due to additive serotonergic effects [8]. It may lower the efficacy of various medications by its action as an inducer of P450 enzymes, especially CYP3A4, leading to lowered plasma levels (Table 12.7). Drug interactions have been seen with alprazolam, amitriptyline, cyclosporine, fexofenadine, indinavir, methadone, simvastatin, tacrolimus, warfarin, and oral contraceptives [59, 64]. St John's wort does not appear to interact with carbamazepine, dextromethorphan, mycophenolic acid, or pravastatin [8].

Hypoglycemia is more likely when St John's wort is used with oral hypoglycemic agents such as glipizide and rosiglitazone. It may induce delirium with loperamide, possibly due to its effects on P-glycoprotein [67]. St John's wort has been reported to trigger mania in bipolar patients [68] and psychosis in schizophrenia [69].

Garlic is commonly utilized for its purported cardiovascular benefits and antiplatelet and antineoplastic activities [70]. It may have modest antihypertensive effects [71]; however, caution is advised when using along with other antihypertensives as it may further lower blood pressure. Garlic has been reported to inhibit platelet aggregation [19], and concurrent use with ASA and clopidogrel has been associated with an increased bleeding tendency [20, 72] although this effect is contested [59].

Ginkgo biloba is a commonly used medicinal plant for memory enhancement, claudication, tinnitus, and vertigo. Like other herbs, there are case reports of increased risk of bleeding when used along with anticoagulant or antiplatelet therapies [73]. However, more rigorous studies have not confirmed a clinically important interaction [59, 39, 74].

Table 12.6 Case reports of drug-dietary supplement interactions

Dietary supplement	Purported mechanism of action/indication	Toxicity/interaction
Black cohosh	Menopausal symptoms	Case reports of hypotension with HCTZ, lisinopril, diltiazem not confirmed in clinical trials, likely safe [58]
Cranberry juice	Acidifies urine, reduce bacterial adherence	Case reports of warfarin and antiplatelet interaction not confirmed by controlled trials [59]
Garlic	HTN, atherosclerosis	Case reports of warfarin and antiplatelet interaction not confirmed by controlled trials [59]
<i>Ginkgo biloba</i>	Increase blood flow; memory promotor	Case reports of warfarin and antiplatelet interaction not confirmed by controlled trials [59]
Ginseng	Memory promotor	Possible bleeding risk with antiplatelet agents [60]
Goldenseal	Anticancer properties	May inhibit action of drugs metabolized by CYP2D6 and 3A4 [61]
Saw palmetto	Reduce Sx of prostatic hypertrophy	Single case report of warfarin interaction, likely safe [59, 62]
Soy	Relief of menopausal symptoms	Possible promotor of estrogen-sensitive tumor growth [63]
St John's wort	Depression, anxiety	Potent CYP3A4 inducer Reduces BCP, simvastatin, warfarin, alprazolam. Delirium with loperamide Serotonin syndrome with SSRI, buspirone [8, 64]

Table 12.7 Other drug-diet interactions

Dietary product	Rx drug	Interaction
Grapefruit juice	Statins	Myalgias, rhabdomyolysis
	Ca channel blocker	Hypotension, bradycardia
	Chemotherapy	Reduced efficacy
	Fexofenadine	Reduce efficacy (OATP inhibition) [65]
Caffeine	SSRI	Irritability, tremor
Hard cheese	MAOIs, selegiline	Serotonin syndrome
St John's wort	Cyclosporine	Lowers plasma levels by PGP and 3A4 induction [35]
St John's wort	Indinavir	Lowers plasma levels by PGP and 3A4 induction [35]
St John's wort	Cyclosporine	Lowers plasma levels by PGP and 3A4 induction [35]

The significance of herb-drug interactions in elderly patients receiving warfarin or in patients taking higher than recommended doses or combinations of herbal medicines is not yet established. Various case reports have shown seizure inducing properties of ginkgo, likely attributed to the 4'-methoxypyridoxine or B6 antivitamin [11]. There is a case report of fatal seizures when combined with valproate and phenytoin [75].

Ginseng has two active ingredients: ginsenosides and eleutherosides, known for its antioxidant and anti-inflammatory effects. It is well tolerated with low side-effect

profile; however, with prolonged use, hypertension, nervousness, sleeplessness, skin eruptions, and morning diarrhea may occur; euphoric and agitated states have been reported. Early reports of decreased warfarin efficacy and manic-like episodes when used with MAO-inhibitors like phenelzine [76] have not been confirmed in later studies [39].

Saw palmetto is marketed as a herbal remedy for benign prostate hypertrophy. It is considered to be a relatively safe herbal medicine; however, case reports of pancreatitis and heart block suggest caution when used in megadoses [77, 78]. Early reports of coagulopathy associated with saw palmetto [79] have not been confirmed in larger clinical studies [39].

False-Positive Urine Drug Testing

Urine drug screening (UDS) is commonly used in a variety of settings, including the workplace, in athletics, criminal settings, and healthcare. Easy access to urine samples makes them ideal for UDS – usually via immunoassay. However, false positives and negatives can occur – often resulting in adverse consequences. For definitive results, gas chromatography-mass spectrometry needs to be utilized.

The Department of Health and Human Services' Guidelines for UDS in the workplace include testing for five substances: amphetamines, cannabinoids, cocaine, opiates, and phencyclidine [80]. In the healthcare settings, UDS for benzodiazepines, alcohol, and tricyclic antidepressants is also common. UDS may be confounded by substituting, diluting, or adulterating urine [81, 82].

Examples of “false positives” in UDS include:

- Using “hemp milk” (sold at health food stores) as a cause of false-positive UDS for cannabinoids.
- Consuming poppy seed pastries may give positive UDS for opiates.
- Dextromethorphan (in OTC cough syrup) may be false positive for opiates.
- Venlafaxine may result in false positive for methamphetamine [83].

Conclusion

People crave autonomy in healthcare and will often reach for the pharmacy aisle before calling a doctor. Patients may be putting themselves at risk for toxicity and drug interactions with the expanding use of herbal medications, OTCs, and dietary supplements. Clinicians need to be aware of potential drug interactions between prescribed and nonprescribed substances. It is important to take a thorough medication history that includes dietary habits, OTCs, supplements, and herbal remedies to predict and prevent potential interactions.

References

1. Cvetanovich GL, Ramakrishnan P, Klein JP, Rao VR, Ropper AH. Reversible cerebral vasoconstriction syndrome in a patient taking citalopram and Hydroxycut: a case report. *J Med Case Rep*. 2011;5(1):34. <https://doi.org/10.1186/1752-1947-5-548>.
2. Center for Food Safety, Nutrition A. Dietary Supplements. <http://www.fda.gov/Food/DietarySupplements/>.
3. Brown AC. An overview of herb and dietary supplement efficacy, safety and government regulations in the United States with suggested improvements. Part 1 of 5 series. *Food Chem Toxicol*. 2017;107(Pt A):449–71. <https://doi.org/10.1016/j.fct.2016.11.001>.
4. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. *JAMA*. 2008;300(24):2867–78. <https://doi.org/10.1001/jama.2008.892>.
5. Espinoza EO, Mann MJ, Bleasdel B. Arsenic and mercury in traditional Chinese herbal balls. *N Engl J Med*. 2009;333(12):803–4. <https://doi.org/10.1056/NEJM199509213331217>.
6. Bent S, Ko R. Commonly used herbal medicines in the United States: a review. *Am J Med*. 2004;116(7):478–85. <https://doi.org/10.1016/j.amjmed.2003.10.036>.
7. Peng CC, Glassman PA, Trilli LE, Hayes-Hunter J, Good CB. Incidence and severity of potential drug–dietary supplement interactions in primary care patients: an exploratory study of 2 outpatient practices. *Arch Intern Med*. 2004;164(6):630–6. <https://doi.org/10.1001/archinte.164.6.630>.
8. Zhou S, Chan E, Pan S-Q, Huang M, Lee EJD. Pharmacokinetic interactions of drugs with St John’s wort. *J Psychopharmacol*. 2016;18(2):262–76. <https://doi.org/10.1177/0269881104042632>.
9. Sheikh HU, Mathew PG. Reversible cerebral vasoconstriction syndrome: updates and new perspectives. *Curr Pain Headache Rep*. 2014;18(5):414. <https://doi.org/10.1007/s11916-014-0414-7>.
10. Thundiyil JG, Kearney TE, Olson KR. Evolving epidemiology of drug-induced seizures reported to a poison control center system. *J Med Toxicol*. 2007;3(1):15–9. <https://doi.org/10.1007/BF03161033>.
11. Jang H-S, Roh SY, Jeong EH, Kim B-S, Sunwoo MK. Ginkgotoxin induced seizure caused by vitamin B6 deficiency. *J Epilepsy Res*. 2015;5(2):104–6. <https://doi.org/10.14581/jer.15018>.
12. Boyer EW, Shannon M. The Serotonin syndrome. *N Engl J Med*. 2009;352(11):1112–20. <https://doi.org/10.1056/NEJMra041867>.
13. Parry GJ, Bredesen DE. Sensory neuropathy with low-dose pyridoxine. *Neurology*. 1985;35(10):1466. <https://doi.org/10.1212/WNL.35.10.1466>.
14. Schaumburg H, Kaplan J, Windebank A, et al. Sensory neuropathy from pyridoxine abuse. *N Engl J Med*. 1983;309(8):445–8. <https://doi.org/10.1056/NEJM198308253090801>.
15. Carol ML. Hydroxycut weight loss dietary supplements: a contributing factor in the development of exertional rhabdomyolysis in three U.S. Army soldiers. *Mil Med*. 2013;178(9):e1039–42. <https://doi.org/10.7205/MILMED-D-13-00133>.
16. Karamadoukis L, Shivashankar GH, Ludeman L, Williams AJ. An unusual complication of treatment with orlistat. *Clin Nephrol*. 2009;71(04):430–2. <https://doi.org/10.5414/CNP71430>.
17. Mangi MA, Rehman H, Rafique M, Illovsky M. Energy drinks and the risk of cardiovascular disease: a review of current literature. *Cureus*. 2017;9(6):e1322. <https://doi.org/10.7759/cureus.1322>.
18. Husain Z, Hussain K, Nair R. Diphenhydramine induced QT prolongation and torsade de pointes: an uncommon effect of a common drug. *Cardiol J*. 2010;17(5):509–11.
19. Saw JT, Bahari MB, Ang HH, Lim YH. Potential drug? herb interaction with antiplatelet/anti-coagulant drugs. *Complement Ther Clin Pract*. 2006;12(4):236–41. <https://doi.org/10.1016/j.ctcp.2006.06.002>.
20. Fakhar H, Hashemi TA. Effect of the garlic pill in comparison with Plavix on platelet aggregation and bleeding time. *Iran J Ped Hematol Oncol*. 2012;2(4):146–52.

21. Pedroso JL, Henriques Aquino CC, Escórcio Bezerra ML, et al. Ginkgo biloba and cerebral bleeding: a case report and critical review. *Neurologist*. 2011;17(2):89–90. <https://doi.org/10.1097/NRL.0b013e3181f097b4>.
22. Finkelstein Y, Goel G, Hutson JR. Drug misuse in adolescents presenting to the emergency department. *Pediatr Emerg Care*. 2017;33(7):451–6.
23. Palamar J. How ephedrine escaped regulation in the United States: a historical review of misuse and associated policy. *Health Policy*. 2011;99(1):1–9. <https://doi.org/10.1016/j.healthpol.2010.07.007>.
24. Costa I, Mendonça MD, Silva VE, Calado S. Herbal supplements association with reversible cerebral vasoconstriction syndrome: a case report. *J Stroke Cerebrovasc Dis*. 2017 Mar;26(3):673–6.
25. Baharith H, Zarrin A. Khat ? A new precipitating factor for reversible cerebral vasoconstriction syndrome: a case report. *J Med Case Rep*. 2016;10(1):1159. <https://doi.org/10.1186/s13256-016-1155-5>.
26. Tuladhar AM, Boogaarts HD, de Leeuw F-E, van Dijk E. Reversible cerebral vasoconstriction syndrome after chewing khat leaves. *Cerebrovasc Dis*. 2013;36(2):158–9. <https://doi.org/10.1159/000353664>.
27. Vrolijk MF, Opperhuizen A, Jansen EHJM, Hageman GJ, Bast A, Haenen GRMM. The vitamin B6 paradox: supplementation with high concentrations of pyridoxine leads to decreased vitamin B6 function. *Toxicol in Vitro*. 2017;44:206–12. <https://doi.org/10.1016/j.tiv.2017.07.009>.
28. Bacharach R, Lowden M, Ahmed A. Pyridoxine toxicity small fiber neuropathy with dysautonomia. *J Clin Neuromuscul Dis*. 2017;19(1):43–6. <https://doi.org/10.1097/CND.0000000000000172>.
29. Chan H, Billmeier GJ, Evans WE. Lead poisoning from ingestion of Chinese herbal medicine. *Clin Toxicol*. 1977;10(3):273–81. <https://doi.org/10.3109/15563657708992423>.
30. Gurley BJ, Steelman SC, Thomas SL. Multi-ingredient, caffeine-containing dietary supplements: history, safety, and efficacy. *Clin Ther*. 2015;37(2):275–301. <https://doi.org/10.1016/j.clinthera.2014.08.012>.
31. Lheureux P, Penalzoa A, Gris M. Pyridoxine in clinical toxicology: a review. *Eur J Emerg Med*. 2005 Apr;12(2):78–85.
32. Lee Y-P, Liao J-T, Cheng Y-W, et al. Inhibition of human alcohol and aldehyde dehydrogenases by acetaminophen: assessment of the effects on first-pass metabolism of ethanol. *Alcohol*. 2013;47(7):559–65. <https://doi.org/10.1016/j.alcohol.2013.09.001>.
33. Haas DA. Adverse drug interactions in dental practice: interactions associated with analgesics, part III in a series. *J Am Dent Assoc*. 1999;130(3):397–407.
34. Honig PK, Gillespie BK. Drug interactions between prescribed and over-the-counter medication I. *Drug Saf*. 1995;13(5):296–303. <https://doi.org/10.2165/00002018-199513050-00003>.
35. Marchetti S, Mazzanti R, Beijnen JH, Schellens JHM. Concise review: clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). *Oncologist*. 2007;12(8):927–41. <https://doi.org/10.1634/theoncologist.12-8-927>.
36. Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR. Pharmacology of dextromethorphan: relevance to dextromethorphan/quinidine (Nuedexta®) clinical use. *Pharmacol Ther*. 2016;164:170–82. <https://doi.org/10.1016/j.pharmthera.2016.04.010>.
37. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. Increased drug delivery to the brain by P-glycoprotein inhibition. *Clin Pharmacol Ther*. 2000;68(3):231–7. <https://doi.org/10.1067/mcp.2000.109156>.
38. Carrillo JA, Benitez J. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. *Clin Pharmacokinet*. 2000;39(2):127–53. <https://doi.org/10.2165/00003088-200039020-00004>.
39. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs. *Drugs*. 2009;69(13):1777–98. <https://doi.org/10.2165/11317010-00000000-00000>.

40. Wilkinson GR. Drug metabolism and variability among patients in drug response. *N Engl J Med*. 2005;352(21):2211–21. <https://doi.org/10.1056/NEJMra032424>.
41. Benotsch EG, Koester S, Martin AM, Cejka A, Luckman D, Jeffers AJ. Intentional misuse of over-the-counter medications, mental health, and polysubstance use in young adults. *J Community Health*. 2013;39(4):688–95. <https://doi.org/10.1007/s10900-013-9811-9>.
42. Mowry JB, Spyker DA, Cantilena LR Jr, McMillan N, Ford M. 2013 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 31st annual report. *Clin Toxicol*. 2015;52(10):1032–283. <https://doi.org/10.3109/15563650.2014.987397>.
43. Weight loss supplements. Amazon. <https://www.amazon.com/Weight-Loss-Products-Nutrition-Fitness/b?ie=UTF8&node=3774931>. Published July 5, 2017. Accessed 7 May 2017.
44. Stevens T, Qadri A, Zein NN. Two patients with acute liver injury associated with use of the herbal weight-loss supplement hydroxycut. *Ann Intern Med*. 2005;142(6):477–8.
45. Araujo JL, Worman HJ. Acute liver injury associated with a newer formulation of the herbal weight loss supplement Hydroxycut. *BMJ Case Reports* 2015. <https://doi.org/10.1136/bcr-2015-210303>.
46. Kockler DR, McCarthy MW, Lawson CL. Seizure activity and unresponsiveness after hydroxycut ingestion. *Pharmacotherapy*. 2001;21(5):647–51.
47. Narasimha A, Shetty PH, Nanjundaswamy MH, Viswanath B, Bada Math S. Hydroxycut? Dietary supplements for weight loss: can they induce mania? *Aust N Z J Psychiatry*. 2013;47(12):1205–6. <https://doi.org/10.1177/0004867413493522>.
48. Dehoney S, Wellein M. Rhabdomyolysis associated with the nutritional supplement Hydroxycut. *Am J Health Syst Pharm*. 2009;66(2):142–8. <https://doi.org/10.2146/ajhp070640>.
49. Hendrickson BP, Shaikh N, Occhiogrosso M, Penzner JB. Mania induced by Garcinia cambogia. *Prim Care Companion CNS Disord*. 2016. <https://doi.org/10.4088/PCC.15101890>.
50. Lopez AM, Kornegay J, Hendrickson RG. Serotonin toxicity associated with *Garcinia cambogia* over-the-counter supplement. *J Med Toxicol*. 2014;10(4):399–401. <https://doi.org/10.1007/s13181-014-0390-7>.
51. Umemura T, Ichijo T, Matsumoto A. Severe hepatic injury caused by orlistat. *Am J Med*. 2006;119(8):e7.
52. Harrison SA, Fecht W, Brunt EM, Neuschwander Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. *Hepatology*. 2009;49(1):80–6. <https://doi.org/10.1002/hep.22575>.
53. Earnshaw I, Thachil J. Example of the drug interaction between ciclosporin and orlistat, resulting in relapse of Evan's syndrome. *BMJ Case Rep*. 2016:bcr2016217246. <https://doi.org/10.1136/bcr-2016-217246>.
54. de Moraes C, de Oliveira CA, Amaral MECD, Landini GA, Catisti R. Liver metabolic changes induced by conjugated linoleic acid in calorie-restricted rats. *Arch Endocrinol Metab*. 2017;61(1):45–53. <https://doi.org/10.1590/2359-399700000186>.
55. FDA warns consumers to stop using hydroxycut products risk of liver injury. <http://www.fda.gov/downloads/NewsEvents/PublicHealthFocus/UCM.pdf>.
56. Semwal RB, Semwal DK, Vermaak I, Viljoen A. A comprehensive scientific overview of *Garcinia cambogia*. *Fitoterapia*. 2015;102:134–48. <https://doi.org/10.1016/j.fitote.2015.02.012>.
57. Guerciolini R. Mode of action of orlistat. *Int J Obes Relat Metab Disord*. 1997;21(Suppl 3):S12–23.
58. Asher GN, Corbett AH, Hawke RL. Common herbal dietary supplement-drug interactions. *Am Fam Physician*. 2017;96(2):101–7.
59. Izzo AA. Interactions between herbs and conventional drugs: overview of the clinical data. *Med Princ Pract*. 2012;21(5):404–28. <https://doi.org/10.1159/000334488>.
60. Yuan C-S, Wei G, Dey L, et al. Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled trial. *Ann Intern Med*. 2004;141(1):23–7.

61. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. *Clin Pharmacol Ther.* 2005;77(5):415–26. <https://doi.org/10.1016/j.clpt.2005.01.009>.
62. Yue QY, Jansson K. Herbal drug curcubin and anticoagulant effect with and without warfarin: possibly related to the vitamin E component. *J Am Geriatr Soc.* 2001;49(6):838.
63. Shike M, Doane AS, Russo L, et al. The effects of soy supplementation on gene expression in breast cancer: a randomized placebo-controlled study. *J Natl Cancer Inst.* 2014;106(9):dju189. <https://doi.org/10.1093/jnci/dju189>.
64. Izzo AA. Drug interactions with St. John's Wort (*Hypericum perforatum*): a review of the clinical evidence. *Int J Clin Pharmacol Ther.* 2004;42(03):139–48. <https://doi.org/10.5414/CP42139>.
65. Shirasaka Y, Mori T, Murata Y, Nakanishi T, Tamai I. Substrate- and dose-dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1. *Pharm Res.* 2014;31(8):2035–43. <https://doi.org/10.1007/s11095-014-1305-7>.
66. Apaydin EA, Maher AR, Shanman R, et al. A systematic review of St. John's wort for major depressive disorder. *Syst Rev.* 2016;5(1):3135. <https://doi.org/10.1186/s13643-016-0325-2>.
67. Khawaja IS, Marotta RF, Lippmann S. Herbal medicines as a factor in delirium. *Psychiatr Serv.* 1999;50(7):969–70. <https://doi.org/10.1176/ps.50.7.969a>.
68. Dalwood J, Dhillon R, Tibrewal P, Gupta N, Bastiampillai T. St John's wort – is it safe in bipolar disorder? *Aust N Z J Psychiatry.* 2015;49(12):1226–7. <https://doi.org/10.1177/0004867415585856>.
69. Stevinson C, Ernst E. Can St. John's wort trigger psychoses? *Int J Clin Pharmacol Ther.* 2004;42(9):473–80.
70. Tattelman E. Health effects of garlic. *Am Fam Physician.* 2005;72:103–6.
71. Ried K, Travica N, Sali A. The effect of aged garlic extract on blood pressure and other cardiovascular risk factors in uncontrolled hypertensives: the AGE at heart trial. *Integr Blood Press Control.* 2016;9:9–21. <https://doi.org/10.2147/IBPC.S93335>.
72. Shafiekhani M, Faridi P, Kojuri J, Namazi S. Comparison of antiplatelet activity of garlic tablets with cardio-protective dose of aspirin in healthy volunteers: a randomized clinical trial. *Avicenna J Phytomed.* 2016;6(5):550–7.
73. Bone KM. Potential interaction of Ginkgo biloba leaf with antiplatelet or anticoagulant drugs: what is the evidence? In: Cott JM, Eisenbrand G, editors. *Mol Nutr Food Res* 2008;52(7):764–71. <https://doi.org/10.1002/mnfr.200700098>.
74. Jiang X, Williams KM, Liauw WS, et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. *Br J Clin Pharmacol.* 2005;59(4):425–32. <https://doi.org/10.1111/j.1365-2125.2005.02322.x>.
75. Kupiec T, Raj V. Fatal seizures due to potential herb-drug interactions with Ginkgo biloba. *J Anal Toxicol.* 2005;29(7):755–8.
76. Kiefer D, Pantuso T. Panax ginseng. *Am Fam Physician.* 2003;68(8):1539–42.
77. Bruminhent J, Carrera P, Li Z, Amankona R, Roberts IM. Acute pancreatitis with saw palmetto use: a case report. *J Med Case Rep.* 2011;5(1):219. <https://doi.org/10.1186/1752-1947-5-414>.
78. Jipescu D, Patel A, Bohra H, Pientka A. Rare case of saw palmetto induced complete heart block. *J Am Coll Cardiol.* 2017;69(11):2310. [https://doi.org/10.1016/S0735-1097\(17\)35699-1](https://doi.org/10.1016/S0735-1097(17)35699-1).
79. Villanueva S, González J. Coagulopathy induced by saw palmetto: a case report. *Bol Asoc Med P R.* 2009;101(3):48–50.
80. Federal register: mandatory guidelines for federal workplace drug testing programs. 2017. <https://www.federalregister.gov/d/2017-00979/p-4>.
81. Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for clinicians. *Mayo Clin Proc.* 2008;83(1):66–76. <https://doi.org/10.4065/83.1.66>.
82. Clinical drug testing in primary care. Substance Abuse and Mental Health Services Administration. [samhsa.gov/shin/content/SMA12-4668/SMA12-4668.pdf](https://www.samhsa.gov/shin/content/SMA12-4668/SMA12-4668.pdf). Published 2012. Accessed 25 Oct 2017.
83. Brahm NC, Yeager LL, Fox MD, Farmer KC, Palmer TA. Commonly prescribed medications and potential false-positive urine drug screens. *Am J Health Syst Pharm.* 2010;67(16):1344–50. <https://doi.org/10.2146/ajhp090477>.